AudioAbstracts

AudioAbstracts by ReachMD provides an easy-to-digest distillation of important medical literature in combination with digital linkage to in-depth information supporting the audio synopsis. AudioAbstracts harnesses the ReachMD digital network to broadcast the spoken synopsis and related digital links through its on-air, online, onsite, and mobile distribution network. Combining quick-read audio synopses with links to source material, AudioAbstracts is the smarter, faster way to stay current on medical literature.

49 episodes

1mo ago latest

monthly cadence

English language

▶ Play latestRSS feed Website Science Medicine Health

https://reachmd.com/rss/itunes/457/?nocache

Episodes 49

4F-PCC Enables Faster VKA Reversal Before Urgent Orthopedic Surgery
1mo ago · 4:30
Host: Matt Birnholz, MD A post hoc analysis of a randomized phase 3b trial evaluated four-factor prothrombin complex concentrate (4F-PCC) versus plasma for urgent vitamin K antagonist (VKA) reversal in adults requiring orthopedic surgery. While both treatments demonstrated comparable hemostatic efficacy and similar safety profiles, 4F-PCC produced substantially faster INR reduction and shortened the median time to surgery by more than 13 hours compared with plasma. These findings add to the growing body of evidence supporting rapid anticoagulation reversal with 4F-PCC in time-sensitive orthope
Rapid and Sustained Symptom Control in CSU with Remibrutinib
1mo ago · 4:15
Despite expanding treatment options, many patients with chronic spontaneous urticaria (CSU) continue to experience persistent itch and hives that can significantly affect their quality of life. Tune in to hear Ryan Quigley review pooled results from the phase 3 REMIX-1 and REMIX-2 studies, highlighting how remibrutinib delivered rapid symptom relief, sustained disease control through one year, and a favorable long-term safety profile for adults with CSU.
Exploring Deeper Silencing in Transthyretin Amyloidosis
2mo ago · 6:00
Guest: Ryan Quigley New real-world data are reshaping the conversation around transthyretin suppression in transthyretin amyloidosis. In this AudioAbstract, Ryan Quigley explains how a crossover analysis revealed substantially deeper serum transthyretin suppression with vutrisiran than patisiran, raising important questions about whether more complete silencing could influence long-term outcomes.
How Symptoms Shape Caregiver Burden in ATTR-CM
2mo ago · 4:15
Host: Ryan Quigley New findings from a post hoc analysis of the Burden of Disease survey highlight how symptom severity and loss of independence in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) contribute to increased caregiver burden, fatigue, anxiety, and depression. In this AudioAbstract, Ryan Quigley discusses which patient-reported symptoms and limitations were most strongly associated with distress and explains why preserving mobility and functional independence may be critical to improving outcomes for both patients and caregivers.
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
5mo ago · 5:30
Host: Hallie Blevins, PhD While transthyretin amyloid cardiomyopathy (ATTR-CM) is often viewed solely as a disorder of protein misfolding, a new review published in the European Heart Journal presents it as a dynamic imbalance between amyloid production and clearance. Hear from Dr. Hallie Blevins as she reviews pivotal data on ATTR-CM's expanding therapeutic landscape.
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
5mo ago · 3:00
Host: Ryan Quigley An April 2025 Current Cardiology Reports article provides new insights into the role of cardiac magnetic resonance (CMR) and genetic data in diagnosing hereditary transthyretin amyloid cardiomyopathy (ATTR-CM). Learn more about this potential approach with Ryan Quigley in this AudioAbstract.
Using Transepidermal Water Loss to Guide Oral Food Challenges
6mo ago · 4:30
Presenter: Ryan Quigley Can real-time transepidermal water loss (TEWL) monitoring reduce the risk of anaphylaxis during oral food challenges in young children with peanut allergy? A pilot trial suggests it may. TEWL-guided stopping significantly lowered anaphylaxis rates and reaction severity without delaying treatment. This benefit was linked to earlier discontinuation of allergen exposure based on physiologic changes, rather than faster intervention. While larger studies are needed, these findings support TEWL monitoring as a promising tool to enhance safety and decision-making during food c
Asthma Immunotherapies: Endotypes, Mechanisms, and Emerging Frontiers
7mo ago · 3:00
Host: Ryan Quigley Distinct immune pathways in T2high and T2low asthma are shaping more precise therapies. To learn more, tune in as Ryan Quigley explores how endotype insights are guiding current and emerging immunotherapy strategies.
Evaluating Structured Interventions for Cognitive Support in MS
7mo ago · 4:00
Host: Hallie Blevins, PhD For patients with multiple sclerosis (MS), cognitive impairment can quietly erode independence and quality of life. In this AudioAbstract, Dr. Hallie Blevins discusses a head-to-head comparison of cognitive training, aerobic exercise, and a combined approach and explores how we can better support cognition in these patients.
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
8mo ago · 3:30
Host: Hallie Blevins, PhD A new analysis from the HEAR registry revealed that tafamidis is associated with significantly improved three-year survival in patients aged 80 and older with transthyretin cardiac amyloidosis (ATTR-CM). Hear from Dr. Hallie Blevins as she discusses this large real-world dataset and the importance of timely recognition and treatment of ATTR-CM in older patients—an often underrepresented group in clinical trials.
From Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
8mo ago · 4:30
Host: Hallie Blevins, PhD A new preclinical study investigated whether Roseburia hominis, a gut microbe often depleted in individuals with obesity, could play a direct role in regulating metabolism. Learn more as Dr. Hallie Blevins explores these findings and their potential implications for future treatment of obesity and related metabolic disorders in this AudioAbstract.
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
8mo ago · 4:15
Guest: Hallie Blevins, PhD In older patients with unexplained hypertrophy, the default diagnosis of hypertrophic cardiomyopathy (HCM) may overlook a common culprit: transthyretin amyloid cardiomyopathy (ATTR-CM). In this AudioAbstract, Dr. Hallie Blevins explores the TTRACK study, which uncovered a striking prevalence of ATTR-CM in patients previously labeled with HCM and affirmed the real-world reliability of nuclear imaging in detecting it. Learn how imaging modalities, tracer choice, and subtle ECG or MRI findings can influence diagnostic accuracy and reshape our clinical approach.
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
8mo ago · 4:30
Host: Ryan Quigley Distinguishing psoriatic arthritis from erosive hand osteoarthritis isn’t always straightforward—but a new imaging approach may help. Tune in to hear Ryan Quigley discuss a recent study assessing fluorescence optical imaging (FOI) and its potential to improve diagnostic accuracy in this challenging clinical scenario.
Progress and Practical Limits with AI in Psoriatic Arthritis
8mo ago · 5:00
Host: Ryan Quigley Artificial intelligence is reshaping the landscape of psoriatic arthritis, offering new tools to improve diagnosis, risk assessment, and treatment response prediction. Hear Ryan Quigley discuss a narrative review that looked at emerging AI innovations in rheumatology and how they may enhance care for patients with psoriatic arthritis.
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
8mo ago · 3:00
Host: Marlene Mimi Maeusli, PhD. Elderly patients with both aortic stenosis and transthyretin cardiac amyloidosis face complex management decisions, but new data suggest that combining aortic valve replacement (AVR) with ATTR-specific therapy may significantly improve outcomes. In this AudioAbstract, Dr. Mimi Maeusli reviews a multinational study published in the European Heart Journal on the prognostic impact of targeted treatment in this dual-diagnosis population and explains how these findings may help guide more informed, individualized treatment strategies.
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
8mo ago · 3:45
Host: Ryan Quigley Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
8mo ago · 5:00
Host: Ryan Quigley How are patients with breast cancer brain metastases faring in the modern treatment era? In this AudioAbstract, Ryan Quigley shares findings from a 25-year review of 507 patients at UCSF, providing new insights into how survival outcomes have shifted across subtypes and which treatments are driving real-world progress. This research was also presented at the 2025 San Antonio Breast Cancer Symposium.
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
8mo ago · 4:00
Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.
Screening for Prediabetes in Youth with Obesity: Evaluating the TyG Index
10mo ago · 5:00
Host: Ryan Quigley A cross-sectional study in Frontiers in Endocrinology assessed the triglyceride–glucose (TyG) index as a potential screening marker for prediabetes in children and adolescents with obesity. Hear from ReachMD's Ryan Quigley as he discusses the findings from this research and explores how the TyG index could provide an accessible tool for early risk stratification.
Adverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
10mo ago · 4:00
Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.
Saliva as a Window Into Cystic Fibrosis: Metabolic Biomarkers and Clinical Potential
10mo ago · 4:00
Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
11mo ago · 4:30
Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
11mo ago · 5:00
Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
11mo ago · 3:15
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Diagnosing Long COVID: Rheumatologic Implications of 2024 Criteria
11mo ago · 5:31
Diagnosing long COVID continues to pose challenges for clinicians and patients alike. While 2024 diagnostic criteria from the National Academies aimed to make navigating it easier, the framework may raise some concerns, particularly for rheumatologists. Hear Ryan Quigley break down a commentary on the criteria published in July 2025 in Arthritis & Rheumatology that outlines why it may cause problems in the rheumatology community.